Project/Area Number |
19590923
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Tazuke Kofukai Medical Research Institute |
Principal Investigator |
TAKEMURA Masaya Tazuke Kofukai Medical Research Institute, 第2研究部, 研究員 (30378707)
|
Co-Investigator(Kenkyū-buntansha) |
FUKUI Motonari 財団法人田附興風会・医学研究所, 第2研究部, 部長 (50342697)
|
Project Period (FY) |
2007 – 2009
|
Project Status |
Completed (Fiscal Year 2009)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2007: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 気管支喘息 / 誘発喀痰 / プロスタノイド / ロイコトリエン / TGFβ / 重症度 / CT / リモデリング |
Research Abstract |
Asthma is a chronic inflammatory disease of the airways, which involves inflammatory mediators such as prostanoids and cysteinyl leukotrienes. We measured the sputum levels eicosanoids in patients with steroid-treated asthma, and investigated the relationships between sputum levels of endogenous eicosanoids and clinical indices such as pulmonary function, airway dimension assessed by chest CT Sputum levels of 6-ketoPGF_<1α>, which is metabolite of PGI_2, were significantly higher (p=0.017) in asthmatic patients (n=41) than in healthy controls (n=9), and showed a marginally negative relation to wall area/body surface area (BSA) (r=-0.62,p=0.063). These results suggest that PGI_2 exert inhibitory effect for airway remodeling in asthma.
|